| Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic … X Sheng, X Yan, Z Chi, L Si, C Cui, B Tang, S Li, L Mao, B Lian, X Wang, ... Journal of Clinical Oncology 37 (32), 2987-2999, 2019 | 171 | 2019 |
| Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients B Tang, X Yan, X Sheng, L Si, C Cui, Y Kong, L Mao, B Lian, X Bai, ... Journal of hematology & oncology 12, 1-15, 2019 | 157 | 2019 |
| The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients B Lian, CL Cui, L Zhou, X Song, XS Zhang, D Wu, L Si, ZH Chi, XN Sheng, ... Annals of Oncology 28 (4), 868-873, 2017 | 144 | 2017 |
| Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti–PD-1 monotherapy X Bai, J Hu, A Betof Warner, HT Quach, CG Cann, MZ Zhang, L Si, B Tang, ... Clinical cancer research 27 (21), 5993-6000, 2021 | 115 | 2021 |
| Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma CN Owen, X Bai, T Quah, SN Lo, C Allayous, S Callaghan, ... Annals of Oncology 32 (7), 917-925, 2021 | 113 | 2021 |
| MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases X Bai, Y Kong, Z Chi, X Sheng, C Cui, X Wang, L Mao, B Tang, S Li, ... Clinical Cancer Research 23 (20), 6120-6127, 2017 | 100 | 2017 |
| Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways X Bai, DE Fisher, KT Flaherty Nature reviews Clinical oncology 16 (9), 549-562, 2019 | 90 | 2019 |
| Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma J Yu, J Yan, Q Guo, Z Chi, B Tang, B Zheng, J Yu, T Yin, Z Cheng, X Wu, ... Clinical Cancer Research 25 (21), 6511-6523, 2019 | 87 | 2019 |
| Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma X Yan, X Sheng, Z Chi, L Si, C Cui, Y Kong, B Tang, L Mao, X Wang, ... Journal of Clinical Oncology 39 (8), 881-889, 2021 | 53 | 2021 |
| MicroRNA-23a-3p inhibits mucosal melanoma growth and progression through targeting adenylate cyclase 1 and attenuating cAMP and MAPK pathways M Ma, J Dai, H Tang, T Xu, S Yu, L Si, C Cui, X Sheng, Z Chi, L Mao, X Wu, ... Theranostics 9 (4), 945, 2019 | 53 | 2019 |
| Multifactorial analysis of prognostic factors and survival rates among 706 mucosal melanoma patients CL Cui, B Lian, L Zhou, X Song, XS Zhang, D Wu, ZH Chi, L Si, XN Sheng, ... Annals of surgical oncology 25, 2184-2192, 2018 | 51 | 2018 |
| Study RC48-C014: Preliminary results of RC48-ADC combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma. L Zhou, H Xu, S Li, X Yan, J Li, X Wu, Z Chi, L Si, C Cui, Y Kong, B Tang, ... Journal of Clinical Oncology 40 (6_suppl), 515-515, 2022 | 46 | 2022 |
| BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma. X Bai, LL Mao, ZH Chi, XN Sheng, CL Cui, Y Kong, J Dai, X Wang, SM Li, ... Neoplasma 64 (4), 626-632, 2017 | 45 | 2017 |
| The clinicopathological and survival profiles comparison across primary sites in acral melanoma X Wei, D Wu, H Li, R Zhang, Y Chen, H Yao, Z Chi, X Sheng, C Cui, X Bai, ... Annals of surgical oncology 27, 3478-3485, 2020 | 44 | 2020 |
| Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis S Li, X Wu, X Yan, L Zhou, Z Chi, L Si, C Cui, B Tang, L Mao, B Lian, ... Journal for Immunotherapy of Cancer 10 (2), 2022 | 41 | 2022 |
| OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study CL Cui, X Wang, B Lian, Q Ji, L Zhou, Z Chi, L Si, X Sheng, Y Kong, J Yu, ... Journal for Immunotherapy of Cancer 10 (4), 2022 | 38 | 2022 |
| Efficacy evaluation of imatinib for the treatment of melanoma: evidence from a retrospective study X Wei, L Mao, Z Chi, X Sheng, C Cui, Y Kong, J Dai, X Wang, S Li, B Tang, ... Oncology Research 27 (4), 495, 2019 | 38 | 2019 |
| Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study F Dimitriou, K Namikawa, ILM Reijers, EI Buchbinder, JA Soon, ... Annals of Oncology 33 (9), 968-980, 2022 | 37 | 2022 |
| Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: a prospective, multicentre, single-arm, phase 2 study X Sheng, D Cao, J Yuan, F Zhou, Q Wei, X Xie, C Cui, Z Chi, L Si, S Li, ... European Journal of Cancer 100, 1-7, 2018 | 37 | 2018 |
| Benefit and toxicity of programmed death‐1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study X Bai, AN Shoushtari, A Betof Warner, L Si, B Tang, C Cui, X Yang, X Wei, ... British Journal of Dermatology 187 (3), 401-410, 2022 | 35 | 2022 |
